Self-assembled drug delivery systems. Part 7: Hepatocyte-targeted nanoassemblies of an adefovir lipid derivative with cytochrome P 450-triggered drug release

International Journal of Pharmaceutics

Volumn 472, Issue 1-2, 2014, Pages 1-9

  Du, Lina ^a   Wu, Lailong ^a,b   Jin, Yiguang ^a,b   Jia, Junwei ^a   Li, Miao ^a   Wang, Yu ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b HENAN UNIVERSITY   (China)

Author keywords

Drug targeting; HBV; HepDirect; Molecular self assembly; Nucleosides

Indexed keywords

ADEFOVIR; ASIALOGLYCOPROTEIN RECEPTOR; CYTOCHROME P450 ISOENZYME; N LAUROYL 1 (3 CHLOROPHENYL) 1,3 PROPANYL PHOSPHONYL ADEFOVIR; UNCLASSIFIED DRUG; ADENINE; ANTIVIRUS AGENT; CYTOCHROME P450; N-LAUROYL-1-(3-CHLOROPHENYL)-1,3-PROPANYL PHOSPHONYL ADEFOVIR; NANOMATERIAL; PHOSPHONIC ACID DERIVATIVE; POLYMER; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; HEPATITIS B; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHILICITY; LIVER CELL; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURFACE CHARGE; TARGET CELL; TISSUE DISTRIBUTION; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CHEMISTRY; LIVER; METABOLISM; NUDE MOUSE;

ADENINE; ANIMALS; ANTIVIRAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DELIVERY SYSTEMS; HEPATITIS B; HEPATOCYTES; LIVER; MALE; MICE, INBRED C57BL; MICE, NUDE; NANOSTRUCTURES; ORGANOPHOSPHONATES; POLYMERS; PRODRUGS; TISSUE DISTRIBUTION;

EID: 84902674046     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.06.020     Document Type: Article

References (36)

1. Y. Barenholz Liposome application: problems and prospects Curr. Opin. Colloid Interface Sci. 6 2001 66 77 (Pubitemid 32233069)
2. A. Chaudhury, S. Das, R.F.S. Lee, K.-B. Tan, W.-K. Ng, R.B.H. Tan, and G.N.C. Chiu Lyophilization of cholesterol-free pegylated liposomes and its impact on drug loading by passive equilibration Int. J. Pharm. 430 2012 167 175
3. G. Cignarella, D. Barlocco, D. Pocar, F. Clerici, M.M. Curzu, G.L. Gessa, F. Fadda, M. Serra, and G. Biggio Synthesis and pharmacological evaluation of a new series of substituted benzoyl-γ-butyrolactone derivatives Eur. J. Med. Chem. 30 1995 721 726
4. K.C. Cundy Clinical pharmacokinetics of the antiviral nucleotide analogs cidofovir and adefovir Clin. Pharmacokinet. 36 1999 127 143 (Pubitemid 29121686)
5. J. Du, Y. Zhou, Q. Fu, W. Gong, F. Zhao, J. Peng, and L. Zhan Bioluminescence imaging of hepatitis B virus enhancer and promoter activities in mice FEBS Lett. 582 2008 3552 3556
6. M.D. Erion, K.R. Reddy, and S.H. Boyer et al. Design, synthesis and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver J. Am. Chem. Soc. 126 2004 5154 5163 (Pubitemid 38509471)
7. M.D. Erion, P.D. van Poelje, D.A. MacKenna, T.J. Colby, A.C. Montag, J.M. Fujitaki, D.L. Linemeyer, and D.A. Bullough Liver-targeted drug delivery using HepDirect prodrugs J. Pharmacol. Exp. Ther. 312 2005 554 560 (Pubitemid 40189552)
8. D. Ganem, and A.M. Prince Hepatitis B virus infection - natural history and clinical consequences N. Engl. J. Med. 350 2004 1118 1129 (Pubitemid 38298992)
9. A. Holy Phosphonomethoxyalkyl analogs of nucleotides Curr. Pharm. Des. 9 2003 2567 2592 (Pubitemid 37456010)
10. T. Ishida, H. Harashima, and H. Kiwada Liposome clearance Biosci. Rep. 22 2002 197 224 (Pubitemid 35222732)
11. Y. Jin, L. Tong, P. Ai, M. Li, and X. Hou Self-assembled drug delivery systems. 1. Properties and in vitro/in vivo behavior of acyclovir self-assembled nanoparticles (san) Int. J. Pharm. 309 2006 199 207 (Pubitemid 43129483)
12. Y. Jin, S. Chen, R. Xin, and Y. Zhou Monolayers of the lipid derivatives of isoniazid at the air/water interface and the formation of self-assembled nanostructures in water Colloids Surf. B Biointerfaces 64 2008 229 235
13. Y. Jin, R. Xin, P. Ai, and D. Chen Self-assembled drug delivery systems. 2. Cholesteryl derivatives of antiviral nucleoside analogues: synthesis, properties and the vesicle formation Int. J. Pharm. 350 2008 330 337
14. Y. Jin, P. Ai, R. Xin, Y. Tian, J. Dong, D. Chen, and W. Wang Self-assembled drug delivery systems. Part 3. In vitro/in vivo studies of the self-assembled nanoparticulates of cholesteryl acyl didanosine Int. J. Pharm. 368 2009 207 214
15. Y. Jin, L. Xing, Y. Tian, M. Li, C. Gao, L. Du, J. Dong, and H. Chen Self-assembled drug delivery systems. Part 4. In vitro/in vivo studies of the self-assemblies of cholesteryl-phosphonyl zidovudine Int. J. Pharm. 381 2009 40 48
16. Y. Jin, N. Qi, L. Tong, and D. Chen Self-assembled drug delivery systems. Part 5: Self-assemblies of a bolaamphiphilic prodrug containing dual zidovudine Int. J. Pharm. 386 2010 268 274
17. Y. Jin, R. Xin, L. Tong, L. Du, and M. Li Combination anti-hiv therapy with the self-assemblies of an asymmetric bolaamphiphilic zidovudine/didanosine prodrug Mol. Pharm. 8 2011 867 876
18. Y. Jin, Y. Lian, and L. Du Self-assembly of n-acyl derivatives of gemcitabine at the air/water interface and the formation of nanoscale structures in water Colloids Surf. A Physicochem. Eng. Aspects 393 2012 60 65
19. C.L. Lai, D. Shouval, and A.S. Lok et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N. Engl. J. Med. 354 2006 1011 1020 (Pubitemid 43357805)
20. M.H. Lee, J.H. Han, P.-S. Kwon, S. Bhuniya, J.Y. Kim, J.L. Sessler, C. Kang, and J.S. Kim Hepatocyte-targeting single galactose-appended naphthalimide: a tool for intracellular thiol imaging in vivo J. Am. Chem. Soc. 134 2012 1316 1322
21. A.S. Lok, M. Hussain, C. Cursano, M. Margotti, A. Gramenzi, G.L. Grazi, E. Jovine, M. Benardi, and P. Andreone Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy Hepatology 32 2000 1145 1153
22. P. Marcellin, T.T. Chang, and S.G. Lim et al. Adefovir dipivoxil for the treatment of hepatitis B antigen-positive chronic hepatitis B N. Engl. J. Med. 348 2003 808 816 (Pubitemid 36245757)
23. S.M. Moghimi, A.C. Hunter, and J.C. Murray Long-circulating and target-specific nanoparticles: theory to practice Pharmacol. Rev. 53 2001 283 318 (Pubitemid 32476118)
24. D.E. Owens, and N.A. Peppas Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int. J. Pharm. 307 2006 93 102 (Pubitemid 41773257)
25. S.D. Pas, E. Fries, R.A. De Man, A.D. Osterhaus, and H.G. Niesters Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays J. Clin. Microbiol. 38 2000 2897 2901 (Pubitemid 30640570)
26. K.R. Reddy, M.C. Matelich, and B.G. Ugarkar et al. Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B J. Med. Chem. 51 2008 666 676 (Pubitemid 351252295)
27. P.C.N. Rensen, L.A.J.M. Sliedregt, M. Ferns, E. Kieviet, S.M.W. van Rossenberg, S.H. van Leeuwen, T.J.C. van Berkel, and E.A.L. Biessen Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo J. Biol. Chem. 276 2001 37577 37584
28. N.D. Santos, C. Allen, and A.-M. Doppen et al. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding Biochim. Biophys. Acta 1768 2007 1367 1377 (Pubitemid 46782695)
29. L.A. Sorbera, N. Serradell, and J. Bolós Pradefovir mesilate Drugs Future 32 2007 137 143
30. J. Thevenot, A.-L. Troutier, L. David, T. Delair, and C. Ladaviere Steric stabilization of lipid/polymer particle assemblies by poly(ethylene glycol)-lipids Biomacromolecules 8 2007 3651 3660 (Pubitemid 350193770)
31. M.J. Valente, F. Carvalho, M.D. Bastos, P.G. de Pinho, and M. Carvalho Contribution of oxidative metabolism to cocaine-induced liver and kidney damage Curr. Med. Chem. 19 2012 5601 5606
32. J. Varshosaz, F. Hassanzadeh, H. Sadeghi, and M. Khadem Galactosylated nanostructured lipid carriers for delivery of 5-fu to hepatocellular carcinoma J. Liposome Res. 22 2012 224 236
33. L. Wang, Q. Fu, and Y. Dong et al. Bioluminescence imaging of hepatitis C virus NS3/4A serine protease activity in cells and living animals Antivir. Res. 87 2010 50 56
34. T. Watanabe, T. Umehara, and F. Yasui Liver target delivery of small interfering RNA to the HCV gene by lactosylated cationic liposome J. Hepat. 47 2007 744 750 (Pubitemid 350051113)
35. W. Wei, Z.G. Yue, and J.B. Qu Galactosylated nanocrystallites of insoluble anticancer drug for liver-targeting therapy: an in vitro evaluation Nanomedicine 5 2010 589 596
36. F. Zhao, S. Liang, Y. Zhou, Y. Wang, H. Yan, X. Wang, H. Wang, J. Du, and L. Zhan Evaluation of hepatitis B virus promoters for sustained transgene expression in mice by bioluminescence imaging Virus Res. 149 2010 162 166